Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Trasylol aprotinin regulatory update

BAY said a joint meeting of FDA's Cardiovascular and Renal Drugs Advisory Committee and Drug Safety and Risk Management Advisory

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE